$RYTM News

Rhythm Pharmaceuticals Announces That Results From Its Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide, A Melanocortin-4 Receptor Agonist, In Patients With Acquired Hypothalamic Obesity Have Been Published In The New England Journal Of Medicine

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141

Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?

Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome - Slideshow

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript

Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151

The Battle Against Genetic Obesity Just Sent This Biotech Stock Flying

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals Presents Data From Multiple Presentations At Endocrine Society's Annual Meeting

Why Is Rhythm Pharma Stock Jumping Today?

Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $155

Reported Saturday, Rhythm Pharmaceuticals Presents Phase 2 Data Showing Setmelanotide Achieves 3.06% Mean BMI Reduction And Clinically Meaningful Hyperphagia Improvements In Prader-Willi Syndrome Patients At ENDO 2026

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

Rhythm Pharmaceuticals To Present Interim Phase 2 Setmelanotide Data In Prader-Willi Syndrome On June 13 At 9:00 a.m. ET

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Updating Its Bardet-Biedl Diagnosis Algorithm

Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine